scholarly journals 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

2016 ◽  
Vol 11 (4) ◽  
pp. S117-S118 ◽  
Author(s):  
K. Park ◽  
E.-H. Tan ◽  
L. Zhang ◽  
V. Hirsh ◽  
K. O'Byrne ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Open Label Trial ◽  
First Line Treatment

First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%

2021 ◽  
Author(s):  
Renaud Descourt ◽  
Christos Chouaid ◽  
Maurice Pérol ◽  
Benjamin Besse ◽  
Laurent Greillier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Egfr Mutations ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without EGFR mutations or ALK rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. Clinical trial number: EudraCT (2020-002626-86); ClinicalTrials.gov ( NCT04547504 ).

Sign in / Sign up

Export Citation Format

Share Document